Sectors
The number of deals in UK spinouts at the earliest stage of equity investing has been falling over the past few years, highlighting a potential bottleneck in early-stage funding.
Launched just a year ago to build on work at Weill Cornell Medicine and New York-Presbyterian Hospital, Cleerly has now closed an oversubscribed series C round.
Cambridge Enterprise has put cash into CardiaTec Biosciences in a pre-seed round that marks the inaugural deal for Laidlaw Scholars Ventures.
Oxford Quantum Circuits' series A round is already among the largest for a European quantum company and could still go higher.
UT Southwestern Medical Center spinout ReCode Therapeutics has now raised a total of $200m in its series B round from investors including Osage University Partners.
University of Washington spinout Zap Energy is working on building a cheap, scalable fusion reactor generating low cost and carbon free energy.
Osage University Partners has added MicroTransponder to a small but mightly portfolio of medical device companies.
Chalmers spinout Elypta is working on a metabolism-based liquid biopsy for early cancer detection that it hopes will catch any type of the disease.
Orphan CNS therapy developer Minoryx Therapeutics closed a $54.8m series C and MIT's The Engine co-led a $10.5m seed round for Foundation Alloy.
Evotec has bought University of Modena and Reggio Emilia spinout Rigenerand for $24.7m.
ZGT has raised $48m from Tsinghua Holdings Capital, CAS Star and others, while University of Cambridge spinout Colorifix has pocketed $22.7m.
The Global University Venturing deal net rounds up the smaller investments from across the university innovation ecosystem.
A roundup of exits, including IPOs and acquisitions, across the tech transfer ecosystem.
The Global University Venturing deal net rounds up the smaller investments from across the university innovation ecosystem.
Oxford Quantum Circuits' series A round is already among the largest for a European quantum company and could still go higher.
MIT spinout Commonwealth Fusion Systems has raised the largest funding round yet for a nuclear fusion developer with investors including The Engine.
Less than a year after raising $72.6m in its series A round, Aerovate Therapeutics has gone public following an IPO worth more than $121m.
Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.
Global University Venturing (GUV) is where tech transfer, academic and investment experts meet to explore the latest ideas and technologies driving innovation forward. We drive the discussions and share best practices that are critical to the success of spinouts, scaleouts and innovation programmes. Our aim is to help improve the processes of bringing innovations from academia to global markets and facilitate their integration into the broader business ecosystem.
